Shares of Divi’s Laboratories Ltd. are in focus on Monday, October 19, on the back of the weight loss drug Orforglipron receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in Europe.
Orforglipron or the drug Foundayo is an Eli Lilly oral weight loss drug.
This development is a positive for Divi’s Laboratories as analysts believe the company is likely to be the intermediate supplier of Orforglipron.
The US Food and Drug Association (USFDA) approved Foundayo for weight-loss on April 1, 2026. The drug has generated $98 million in global sales in the second quarter of 2026, divided between $67 million in the US and $31 million in the UAE.
Divi’s Laboratories is yet to disclose when it is set to report its earnings for the September quarter.
However, in the first quarter of this fiscal, it reported a strong performance, with its consolidated net profit rising 65.6% to ₹902 crore from ₹545 crore last year. It was also higher than the CNBC-TV18 pol of ₹657 crore.
Its revenue operations was up 27.8% at ₹3,080 crore from ₹2,410 crore in the first quarter of the last fiscal. It too exceeded estimates of ₹2,911 crore.
Its earnings before interest, taxes, depreciation and amortization (EBITDA) increased 72.2% to ₹1,255 crore from ₹729 crore and was significantly ahead of the CNBC-TV18 poll of 915 crore.
Shares of Divi’s Laboratories ended the previous session 1.3% higher at ₹9,144.5 apiece. The stock has declined 2.8% in the past month and is up 44.1% this year, so far.
Also Read: HCG, Apollo Hospitals, Max, Fortis Health share price could see further pressure today; Here’s why
Gold, silver prices today: What could drive bullion rates this week
Oct 19, 2026
Q2 Results LIVE Updates: HDFC, ICICI, Axis, Yes Bank react to earnings; UltraTech, Bajaj Fin report today
Oct 19, 2026
HCG, Apollo Hospitals, Max, Fortis Health share price could see further pressure today; Here’s why
Oct 19, 2026
Asian stocks fall as tech rout, China data and earnings weigh on sentiment; Nikkei down over 2%
Oct 19, 2026